What is the typical Orforglipron dosage?

Published protocols describe 3–36 mg daily, given oral tablet. This is context from the literature, not a recommendation: a licensed provider sets the dose.

What are the side effects of Orforglipron?

Risks noted for Orforglipron include nausea, vomiting, diarrhea, and constipation. Tell your provider about your medications and conditions before starting.

What is the half-life of Orforglipron?

The reported half-life is ~29–49 hours. Onset is typically reported at 2–4 weeks for appetite reduction.

GLP-1 · SMALL MOLECULE

What is Orforglipron?

Medically reviewed by the G1 Peptides clinical team · Updated October 1, 2026

THE SHORT ANSWER

Orforglipron is an investigational GLP-1 receptor agonist taken as a daily tablet. Unlike semaglutide and tirzepatide it is a small molecule, not a peptide, so it does not need to be injected or taken on an empty stomach.

Orforglipron at a glance

Type: Small molecule
Also known as: LY3502970
Mechanism: Oral non-peptide GLP-1 receptor agonist
Status: Phase 3
Half-life: ~29–49 hours
Route: Oral tablet
Dosing range in the literature: 3–36 mg daily
Onset: 2–4 weeks for appetite reduction
Storage: Room temperature

How Orforglipron works

It activates the same GLP-1 receptor as injectable drugs in this class, reducing appetite and improving blood-sugar control. Because it is not a peptide, it survives digestion and is absorbed like an ordinary tablet.

What Orforglipron is studied for

Weight management
Type 2 diabetes
No injections

Phase 3 trials reported average weight loss of roughly 12% over 72 weeks at the highest dose, along with improved blood-sugar control in type 2 diabetes.

Being studied for something is not proof that it works. Results in individuals vary.

Orforglipron dosing

Published protocols describe 3–36 mg daily, once daily (oral), given oral tablet. Onset is typically reported at 2–4 weeks for appetite reduction.

These figures are context from the literature, not instructions. A licensed provider sets the dose and schedule for each patient.

Orforglipron dosage calculator →

Orforglipron side effects and risks

Nausea
Vomiting
Diarrhea
Constipation

Tell your provider about every medication and condition before starting, and report anything unexpected. See peptide side effects and safety and who should not use peptides.

Is Orforglipron FDA approved?

A late-stage investigational drug at the time of review. Approval status in this class is changing quickly; check the FDA for the current position.

Approval and trial status change. This page was last reviewed on October 1, 2026.

Orforglipron at G1 Peptides

G1 Peptides does not currently supply Orforglipron. A provider can discuss alternatives in a free consultation.

Orforglipron questions

What is Orforglipron?: Orforglipron is an investigational GLP-1 receptor agonist taken as a daily tablet. Unlike semaglutide and tirzepatide it is a small molecule, not a peptide, so it does not need to be injected or taken on an empty stomach.
What is Orforglipron used for?: Orforglipron is studied for weight management, type 2 diabetes, and no injections. Phase 3 trials reported average weight loss of roughly 12% over 72 weeks at the highest dose, along with improved blood-sugar control in type 2 diabetes.
How does Orforglipron work?: It activates the same GLP-1 receptor as injectable drugs in this class, reducing appetite and improving blood-sugar control. Because it is not a peptide, it survives digestion and is absorbed like an ordinary tablet.
Is Orforglipron FDA approved?: A late-stage investigational drug at the time of review. Approval status in this class is changing quickly; check the FDA for the current position.
What is the typical Orforglipron dosage?: Published protocols describe 3–36 mg daily, given oral tablet. This is context from the literature, not a recommendation: a licensed provider sets the dose.
What are the side effects of Orforglipron?: Risks noted for Orforglipron include nausea, vomiting, diarrhea, and constipation. Tell your provider about your medications and conditions before starting.
What is the half-life of Orforglipron?: The reported half-life is ~29–49 hours. Onset is typically reported at 2–4 weeks for appetite reduction.
How should Orforglipron be stored?: Room temperature.

For educational purposes only, and not medical advice. These statements have not been evaluated by the FDA. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease. Use any compound only under the guidance of a licensed provider.